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Abstract
Objective: The prominent histopathological feature of the amyotrophic lateral
sclerosis (ALS) is the presence of intracellular inclusions in degenerating neu-
rons and their axons. The appearance and localization of these pathological
structures depend on an aggregated protein that forms their scaffold. We inves-
tigated if c-synuclein, an aggregation-prone protein highly expressed in healthy
motor neurons, and predominantly localized in their axons and synaptic termi-
nals is involved in ALS pathology. Methods: Immunostaining of histological
sections and sequential protein extraction from postmortem neural samples
followed by immunoblotting. Results: Immunohistochemical screening revealed
a subset of sporadic (9 of 31) and familial (8 of 23) ALS cases with a novel type
of pathology characterized by the accumulation of c-synuclein in distinct
profiles within the dorsolateral column. Sequential fractionation of proteins
from the spinal cord tissues revealed detergent-insoluble c-synuclein species
specifically in the dorsolateral corticospinal tracts of a ALS patient with
c-synuclein-positive profiles in this region. These profiles are negative for pro-
tein markers commonly found in pathological inclusions in the spinal cord of
ALS patients and most probably represent degenerated axons of upper motor
neurons that have lost their neurofilaments. A subset of these profiles was
found in association with phagocytic cells positive for Mac-2/Galectin-3. A
smaller subset of studied ALS cases (4 of 54) contained large cytoplasmic inclu-
sions in the cell body of remaining spinal motor neurons. Interpretation: Our
observations suggest that pathological aggregation of c-synuclein might contrib-
ute to the pathogenesis of ALS.
Introduction
Amyotrophic lateral sclerosis (ALS) is a devastating motor
neuron disease characterized by the selective loss of dis-
crete populations of upper and lower motor neurons. A
histopathological hallmark of both familial (fALS) and the
more common sporadic (sALS) forms of the disease is the
presence of distinctive intracellular inclusions in degener-
ating neurons and their axons. Formation of these
pathological structures has been linked with the accumula-
tion and aggregation of several proteins, including those
mutated in fALS, namely SOD1,1 TDP-43,2 FUS/TLS,3,4
neurofilament subunits,5 optineurin,6,7 ubiquilin-28 and
even dipeptide products of unconventional repeat-associated
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non-ATG initiated translation of GGGGCC repeats in
C9ORF72 locus.9,10 However, some proteins that are constit-
uents of pathological inclusions have never been genetically
associated with fALS or predisposition to sALS, examples
include p38MAPK,11 galectin-1,12 Smad2/3,13 RBM4514 and
p54nrb/NONO.15 It is likely that other, yet to be identified
proteins may be involved in ALS pathology.
c-Synuclein presents a feasible candidate for such a
protein due to an auspicious combination of properties.
Structurally it is closely related to a-synuclein and shares
its ability to aggregate in vitro16,17 and in vivo,18 which is
believed to be a crucial trigger of neurodegeneration in a-
synucleinopathies. Motor neurons express high levels of
c-synuclein, with the protein highly abundant in their
axons, where it might affect organization of axonal
cytoskeleton.18–21 Axonal or periaxonal accumulation of
c-synuclein has been found to accompany major
histopathological changes in several neurodegenerative
diseases.22–24 Finally, genetically unaltered c-synuclein
aggregates, fibrillates and forms axonal and perikaryal
inclusions when overexpressed in neurons of transgenic
mice, which is coupled with progressive and selective loss
of motor neurons and the development of motor defi-
ciency.18,25 We therefore undertook a search for any
evidence of c-synuclein pathology in patients with
sporadic and familial ALS, a disease where such pathology
has not yet been assessed, using a set of previously histo-
pathologically characterized spinal cord samples.
Materials and Methods
Patient data and analysis of tissue samples
Human tissue samples were obtained from the MRC Lon-
don Neurodegenerative Diseases Brain Bank and Sheffield
Brain Tissue Bank. Consent was obtained from all sub-
jects for autopsy, histopathological assessment and
research in accordance with local and national Ethics
Committee approved donation. For each case a detailed
post-mortem histopathological report produced by a
qualified pathologist was obtained after completion of the
primary assessment of c-synuclein staining that was car-
ried out blindly. The spinal cord tissues were histologi-
cally assessed from 31 cases of sALS (21 males, 10
females; mean ageSEM 65.2  1.9 years, mean post-
mortem delay  SEM 34.7  4.1 h), 17 cases of fALS
with C9ORF72 expansion (nine males, eight females;
mean age  SEM 62.2  2.2 years, mean post-mortem
delay  SEM 37.6  7.6 h); three cases of SOD1-fALS
(one male, two females; mean age  SEM 53.7 
7.7 years, mean post-mortem delay  SEM 27.7 
18.4 h), three cases of FUS-fALS (one male, two females;
mean age  SEM 34.3  0.7 years, mean post-mortem
delay  SEM 38.3  16.4 h), six Alzheimer’s disease
cases (three males, three females; mean age  SEM
76.7  4.4 years, mean post-mortem delay  SEM
26.2  8.5 h), one Lewy body dementia case (male; age
88 years, post-mortem delay 18 h), one Parkinson’s dis-
ease case (male, age 74, post-mortem delay 10 h) and 13
control cases with no clinical history or histological evi-
dence of neurodegeneration (eight males, five females;
mean age  SEM 68.7  3.4 years, mean post-mortem
delay  SEM 46.5  7.3 h). For details of ALS and con-
trol cases see Table 1.
Primary antibodies
Anti-human c-synuclein rabbit-polyclonal SK109 anti-
body21 was used at 1:250 dilution for immunohistochem-
istry, 1:100 dilution for immunofluorescence and 1:500
dilution for Western blotting. Anti-human c-synuclein
goat-polyclonal E20 antibody (Santa Cruz Biotechnology
Inc., Dallas, TX) was used at 1:100 dilution for immuno-
histochemistry and 1:250 dilution for Western blotting.
To prove the specificity of c-synuclein staining some sec-
tions were immunostained with SK109 or E20 antibody
preincubated for 1-h with purified recombinant human
c-synuclein at 0.1 mg/mL concentration. Anti-ubiquitin
mouse monoclonal Ubi-1 antibody (Zymed Laboratories
Inc., South San Francisco, CA) was used at 1:100 dilution
for immunohistochemistry and immunofluorescence.
Anti-phospho(S409/410-2)TDP-43 rabbit-polyclonal anti-
body (Cosmo Bio Co. Ltd., Tokyo, Japan) was used at
1:3000 dilution for immunohistochemistry. For immuno-
fluorescence, anti-neurofilaments mouse monoclonal
SMI312 antibody (Covance, Princeton, NJ) was used at
1:100 dilution, anti-Mac-2/Galectin-3 mouse monoclonal
B2C10 antibody (BD Pharmigen, Jose, CA) – at 1:100
dilution and anti-p62 mouse monoclonal clone 3 anti-
body (BD Pharmigen) – at 1:100 dilution.
Histological techniques
Eight-lm thick sections of 10% formalin-fixed paraffin-
embedded cervical and thoracic spinal cord and primary
motor cortex were processed and immunostained as
described previously.18,21 Immunohistochemical detection
was carried out using Elite plus kits (Vector Laboratories,
Burlingame, CA) and 3,30-diaminobenzidine as a substrate
(Sigma-Aldrich, St. Louis, MO). For immunofluorescent
detection anti-rabbit and anti-mouse secondary antibodies
conjugated to Alexa Fluor 488 or Alexa Fluor 546 or Alexa
Fluor 633 (Invitrogen, Carlsbad, CA) were used at 1:1000
dilution and images were collected sequentially on a Leica
TCS SP2 laser scanning confocal microscope (Leica Micro-
systems, CMS, GmbH, Mannheim, Germany).
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Sequential protein extraction
A previously described protocol18 was used with minor
modifications. Briefly, frozen neuronal tissues were
homogenized in five volumes of high salt buffer
(50 mmol/L Tris–HCl, pH 7.5; 750 mmol/L NaCl;
5 mmol/L EDTA) with protease inhibitors (Complete
Mini from Roche Diagnostics Limited, Burgess Hill, UK)
and centrifuged at 12,000g for 15 min at 4°C. The super-
natant (PMS fraction) was centrifuged at 100,000g for
20 min at 4°C. The high-speed supernatant represented
high salt soluble (HS) fraction. The pellet was washed in
Table 1. Summary of sALS, fALS, and control cases assessed in this
study.
Case Sex Age PMD
Corticospinal
tract c-
synuclein-
positive
profiles
c-synuclein-
positive
inclusions
in motor
neuron
cell bodies
c-synuclein
amino acids
encoded by
allelic variants
(SNP in the
exon IV)
Amyotrophic lateral sclerosis with SOD1 mutation
01 F 46 5   Glu/Glu
02 F 69 64 +  Glu/Glu
03 M 46 14 +  Glu/Glu
Amyotrophic lateral sclerosis with FUS mutation
04 F 35 20   Glu/Glu
05 M 33 71   Glu/Val
06 F 35 24   Glu/Glu
Amyotrophic lateral sclerosis with hexanucleotide expansion in
C9ORF72 locus
59 M 72 96 +  Val/Val
60 M 46 4  + Val/Val
61 M 59 60 +  Glu/Val
62 F 58 2   Glu/Glu
63 M 46 15  + Val/Val
64 F 76 10   Glu/Val
65 F 64 N/A   Glu/Glu
66 F 62 63 +  Glu/Val
67 F 64 7 +  Glu/Glu
68 M 72 96   Val/Val
69 F 69 55 +  Val/Val
70 M 48 23   Glu/Glu
71 F 67 24   Glu/Glu
72 F 64 7   Glu/Glu
73 M 68 31 + + Glu/Glu
74 M 64 48   Glu/Val
75 M 59 60   Glu/Val
Sporadic amyotrophic lateral sclerosis
07 M 61 44   Glu/Val
08 M 71 58   Glu/Val
09 M 82 13   Val/Val
10 F 57 48   Glu/Glu
11 M 55 54   Glu/Val
12 F 78 69   Glu/Glu
13 M 72 19   Glu/Val
14 F 80 37   Glu/Val
15 M 68 8 +  Glu/Val
16 M 60 53 +  Glu/Val
17 F 68 49 +  Glu/Glu
18 M 72 26 +  Glu/Glu
19 M 78 2 +  Glu/Val
20 M 59 77 +  Glu/Glu
21 M 67 70 +  Glu/Val
22 M 73 42 +  Glu/Glu
44 F 59 30  + Glu/Glu
45 M 70 86   Glu/Glu
46 M 68 N/A   Glu/Val
47 F 69 12   Glu/Glu
48 M 66 8   Glu/Glu
(Continued)
Table 1. Continued.
Case Sex Age PMD
Corticospinal
tract c-
synuclein-
positive
profiles
c-synuclein-
positive
inclusions
in motor
neuron
cell bodies
c-synuclein
amino acids
encoded by
allelic variants
(SNP in the
exon IV)
49 M 65 9   Glu/Glu
50 F 41 24   Glu/Val
51 F 75 24   Glu/Glu
52 M 79 24   Val/Val
53 M 51 N/A   Glu/Val
54 M 51 N/A   Glu/Val
55 M 53 16   Glu/Glu
56 F 70 24 +  Glu/Glu
57 M 51 22   Glu/Glu
58 F 51 24   Glu/Glu
Normal control (no evidence of neurological pathology)
23 F 90 50   Glu/Glu
24 M 62 80   N/A
25 F 79 73   N/A
26 M 64 71   N/A
27 M 80 48   Glu/Glu
28 F 55 95   N/A
29 M 54 31   Glu/Val
30 M 79 24   N/A
39 M 64 12   Glu/Glu
40 F 62 36   Glu/Val
41 M 78 43   Glu/Glu
42 M 51 25   Glu/Glu
43 F 75 16   Glu/Val
Non-ALS neurodegenerative diseases
31 M 75 6   N/A
32 M 62 44   N/A
33 F 93 6   N/A
34 M 75 55   N/A
35 F 71 33   N/A
36 F 84 13   N/A
37 M 88 18   N/A
38 M 74 10   N/A
N/A, data unavailable; , negative; +, positive; fALS, familial amyo-
trophic lateral sclerosis; sALS, sporadic amyotrophic lateral sclerosis.
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the same high salt buffer and re-extracted with high salt
buffer containing 1% Triton-X100. The high-speed centri-
fugation produced the supernatant (HS/T fraction) and
the pellet that was subsequently washed in HS/T buffer
and re-extracted with RIPA buffer (50 mmol/L Tris-HCl,
pH 8.0; 150 mmol/L NaCl; 5 mmol/L EDTA; 1% NP40;
0.5% SDS) as above to obtain RIPA soluble (RIPA) frac-
tion. The final pellet was washed in RIPA buffer, resus-
pended in a gel loading buffer with 2% SDS and incubated
in a boiling water bath for 10 min (SDS fraction). Aliquots
of other fractions were mixed with an equal volume of 29
gel loading buffer and boiled for 5 min before loading on
a 16% SDS-PAGE. The level of c-synuclein in fractions
was assessed by Western blotting using SK109 rabbit-poly-
clonal antibody as described previously.26
Results
Immunohistochemical assessment of transverse spinal
cord sections representing 31 sporadic and 23 familial
cases revealed a group of nine sALS and eight fALS
patients with unusual structures, which were intensely
stained by two antibodies that recognize human c-synuc-
lein (Fig. 1A–D). High specificity of SK109 antibody has
been demonstrated in our previous studies26,27 and prein-
cubation of antibodies with recombinant human c-synuc-
lein (Fig. 1D) but not other recombinant synucleins (data
not shown) abolished this staining. The occurrence of
these c-synuclein-positive profiles was restricted to the
corticospinal tract in the dorsolateral column of the
spinal cord (Fig. 1A). No such profiles were observed in
any of studied 21 control spinal cord tissues from healthy
individuals or patients with unrelated neurodegenerative
diseases (see Materials and Methods and Table 1 for
details). Occasional Corpora amylacea were detected
within the corticospinal tracts, however, the morphology
and distribution of these bodies did not match that of the
c-synuclein-positive profiles. Generally round or slightly
elliptical shape of profiles detected on transverse sections
may suggest that they represent either small spheroid-
shaped structures or transsections of rod-like structures
orientated along the spinal cord rostrocaudal axis. Immu-
nostaining of longitudinal sections along the rostrocaudal
axis of spinal cords prepared from re-orientated paraffin
blocks of three patients with c-synuclein-positive profiles
revealed elongated or rod-like c-synuclein-positive struc-
tures, which thickness (~10 lm) accurately correlated
with the diameter of profiles seen on transverse sections
(Fig. 1E). Taking into consideration high abundance of
c-synuclein in axons of many types of neurons18–21 it was
feasible to suggest that observed structures represented
damaged axons. However, double immunofluorescent
staining demonstrated that these structures are negative
for a pan-axonal neurofilament marker (Fig. 2A and B),
indicating that they are not simply damaged axons but
products of a more specific accumulation/aggregation
process. Further double immunofluorescent or immuno-
histochemical staining of parallel sections with antibodies
against c-synuclein and proteins that often aggregate
in the nervous system of ALS patients demonstrated that
c-synuclein-positive profiles detected within the dorsolat-
eral column are negative for TDP-43, p62 and ubiquitin,
although in a number of cases typical inclusions stained
for these proteins were frequent in the anterior horn
motor neurons in the same sections (Figs. 1F, G and 2C).
Retrospective analysis of the available clinical and histo-
pathological data showed that in sALS these profiles were
present not only in the more common cases with
Figure 1. Immunohistochemical staining of sections through cervical
spinal cord of ALS patients demonstrated selective presence in the
dorsolateral corticospinal tract region (A) of rounded, unevenly
stained c-synuclein-positive profiles (insert). These profiles could be
revealed using either rabbit-polyclonal antibodies (SK109, B and E) or
goat-polyclonal antibodies (E20, C) and preincubation of antibodies
with recombinant human c-synuclein abolished staining (D).
Immunostaining of sections cut through the corticospinal tract region
along the rostrocaudal axis revealed elongated or rod-shaped c-
synuclein-positive profiles (white arrowheads in E). Immunostaining
for ubiquitin (F) or phosphorylated TDP-43 (G) failed to detect large
ubiquitinated profiles (comparable to those containing c-synuclein) in
the lateral corticospinal tracts of patients, although in the same
sections ubiquitinated skein-like inclusions (Fi) or cytoplasmic TDP-43-
positive structures (Gi) were observed in the ventral horn motor
neurons. (A) represents case 19, (B, C, D, F) represent case 18, (E)
represents case 67 and (G) represents case 22. Scale bars = 1 mm for
A-left, 100 lm for A-right, 10 lm for the inset in A and 50 lm for
B–G. ALS, amyotrophic lateral sclerosis.
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profound loss of upper motor neurons (observed in 4 of
11 analyzed cases), but also in cases with insignificant loss
of these cells (observed in 4 of 5 analyzed cases). Further-
more, c-synuclein-positive profiles were detected in sALS
cases with either mild or severe myelin pallor, suggesting
that there is no correlation between their presence and
the severity of damage to descending motor fibers.
Within the profiles the staining was observed to have
a mesh-like appearance (Figs. 1, 2) suggesting that they
might be composed of aggregated c-synuclein. To
biochemically assess for the presence of aggregated
c-synuclein species we carried out sequential protein
fractionation on tissue samples dissected from the fro-
zen spinal cord of a sALS patient histologically proven
to be positive for c-synuclein-positive profiles in the
dorsolateral column but not in the anterior horn (case
15). Western blot analysis of these protein fractions
revealed the presence of c-synuclein in the detergent-
insoluble fraction of tissues dissected from the dorsolat-
eral column, but not from the anterior horn areas
(Fig. 3). The large amounts of c-synuclein seen in the
soluble fractions should be attributed to high levels of
this protein in multiple healthy or less damaged axons
located in the dissected areas of the spinal cord. The
presence of c-synuclein species with slow mobility in
the denaturing SDS–PAGE was not typical even for the
detergent-insoluble fractions, probably reflecting an
intrinsic feature of aggregates formed by c-synuclein, as
such high molecular mass species were previously found
to be scarce even in the spinal cord samples of c-synuc-
lein transgenic mice with a high burden of pathological
c-synuclein aggregates.18 Similar analysis detected c-syn-
uclein in the detergent-insoluble fraction extracted from
the dorsolateral column of another profiles-positive
sALS case but not in a profiles-negative sALS or healthy
control cases, representative Western blots are shown in
Figure S1. We also detected detergent-insoluble c-synuc-
lein in the motor cortex of patients with FTLD-MND
(Fig. S1).
Figure 2. Immunofluorescent staining of the dorsolateral
corticospinal tract region of ALS cases for c-synuclein (SK109
antibody) and various marker proteins. Double immunostaining with
pan-axonal neurofilament marker (NF) showed the absence of c-
synuclein co-localization with axonal neurofilaments within the rod-
like c-synuclein-positive profiles (large arrowheads) on sections cut
through the corticospinal tract region along the rostrocaudal axis (A,
case 67) or on transverse sections (B, case 19). Note strong
neurofilament staining of multiply healthy looking axons on these
sections with different degree of co-staining for c-synuclein (arrows
show axons strongly positive for both NF and c-synuclein, and small
arrowheads show axons strongly positive for NF but weakly for c-
synuclein). c-synuclein-positive profiles were also negative for p62 (C,
case 18) although p62-positive skein-like inclusions were detected in
the anterior horn motor neurons (inset, small arrows) on the same
section. Some c-synuclein-positive profiles were found engulfed by
cells positive for phagocytic activity marker Mac-2/Galectin-3 (D –
arrow, case 02). Secondary anti-mouse antibody conjugated with
Alexa Fluor 546 (A) or Alexa Fluor 633 (B–D) were utilized to assess
co-localization of different proteins with c-synuclein detected using
secondary anti-rabbit antibody conjugated with Alexa Fluor 488. Scale
bars = 10 lm for B and 20 lm for A, C, D and the inset in C. ALS,
amyotrophic lateral sclerosis.
Figure 3. Detection of c-synuclein in post-mitochondrial supernatant
(PMS) and fractions obtained from it by sequential extraction with
high salt (HS), high salt/Triton-X100 (HS/T), RIPA buffer (RIPA) and
boiling in 2% SDS (SDS). A Western blot probed with SK109 antibody
(A) shows the presence of detergent-insoluble c-synuclein species in
the area of corticospinal tract (dorsolateral column) but not anterior
horn of the spinal cord of the ALS patient (case 15). Sizes of protein
markers visible as white shades in the middle lane of the Western blot
are shown in kDa on the right.
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DAPI-positive nuclei were occasionally observed in
close proximity to c-synuclein-positive rod-like structures
on longitudinal sections (Fig. 2A). In transverse sections
partial overlap of some nuclei with c-synuclein-positive
profiles was seen (Fig. 2B and C), suggesting that certain
phagocytic cells envelop or internalize fragments of these
structures. Internalization of axon-derived c-synuclein
aggregates by specialized astrocytes in the optic nerve of a
mouse model of glaucoma28 and it is feasible that a simi-
lar process might take place in the dorsolateral column of
the spinal cord of ALS patients. A staining pattern com-
patible with this hypothesis was revealed by co-immuno-
staining for c-synuclein and Mac-2/galectin-3 (Fig. 2D), a
marker of phagocytic cells, which has also been previously
linked to ALS.29
A pale diffuse cytoplasmic c-synuclein staining charac-
teristic for spinal motor neuron cell bodies of healthy
individuals is also typical for the majority of remaining
spinal motor neurons in ALS patients (Fig. 4A). However,
in one sALS and three fALS cases with C9ORF72 repeat
expansion (see Table 1) we found motor neurons with
large c-synuclein-positive cytoplasmic inclusions (Fig. 4A
and B). Only in one of these cases c-synuclein-positive
profiles in the corticospinal tract were also present. No
clinical characteristics that clearly distinct these four from
other studied ALS cases were noted (Table S1). Retrospec-
tive analysis of available histopathological data revealed
that in spinal motor neurons of these four patients, p62-
and TDP-43-positive inclusions were more abundant than
rarely observed c-synuclein-positive inclusions, suggesting
that these are different structures. We did not found cyto-
plasmic inclusions stained by c-synuclein antibody in
upper motor neurons of several studied sALS cases but in
one of them (case 18) c-synuclein-positive ballooned neu-
ritis and amorphous extracellular deposits were observed
in the motor cortex (Fig. 4C). Finally, we also found no
correlations between the presence of cytoplasmic inclu-
sions or corticospinal tract profiles and the presence of
human c-synuclein allelic variants encoding either valine
or glutamic acid in the position 110 of the protein amino
acid sequence (Table 1).
Discussion
We identified a novel histopathological feature of ALS,
c-synuclein-positive structures present in the spinal cord
of approximately 30 percent of ALS patients we assessed.
The most abundant (found in 17 of 58 cases included in
this study) were pathological profiles that present exclu-
sively in the dorsolateral column where the descending
axons of upper motor neurons are localized. They have a
distinct morphology and could be revealed by immuno-
staining with antibodies specific to c-synuclein, but not
with antibodies to other proteins typically associated with
ALS pathology. Large c-synuclein-positive inclusions in
the cell bodies of some spinal motor neurons were
observed in fewer ALS cases (4 of 58) and only in one
case were both types of structures found.
Although c-synuclein is not a constituent of histopath-
ological hallmarks in any neurodegenerative diseases,
abnormal structures positive for this protein have been
observed in the brain of some patients with Parkinson’s
disease, Lewy body dementia and Hallervorden-Spatz syn-
drome.22,23 However, the profiles we describe in the
spinal cord of ALS patients are clearly different from pre-
viously described c-synuclein-positive structures in these
diseases. The axonal spheroids seen in the stratum molec-
ulare of the dentate gyrus of Parkinson’s disease and Lewy
Figure 4. Immunohistochemical staining of anterior horn motor
neurons and motor cortex of ALS patients with antibodies against c-
synuclein. On two adjacent sections through the spinal cord of a sALS
patient (case 60) E20 goat-polyclonal antibodies detect diffuse
cytoplasmic staining in the cell body of a motor neuron in the left
bottom corner and large inclusions (arrows) in the cell body of a
motor neuron in the right top corner (A). Similar cytoplasmic
inclusions were revealed in motor neurons of case 63 (B, left panel)
and case 73 (B, middle and right panels) fALS patients with C9ORF72
repeat expansion using SK109 rabbit-polyclonal antibodies. In the
motor cortex of a sALS patient (case 18), c-synuclein-positive
ballooned neurites (left panel) and amorphous deposits (right panel)
were detected using SK109 antibody. Scale bars = 50 lm for A, B
and 10 lm for C. fALS, familial amyotrophic lateral sclerosis; sALS,
sporadic amyotrophic lateral sclerosis.
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body dementia cases were several times smaller and
pretreatment of sections with formic acid was necessary
for their detection.23 Spheroids detected using an anti-
body against c-synuclein in the cingulate and midfrontal
cortices of patients with Hallervorden-Spatz syndrome
were also detected with antibodies to NF proteins and
ubiquitin,22 whereas c-synuclein-positive profiles in the
dorsolateral column of ALS patients were negative for
these proteins. Thus, these newly identified profiles repre-
sent a truly novel histopathological feature of neurode-
generative diseases. Because these profiles were found in
both sALS, SOD1-fALS and C9ORF72-fALS cases it might
be concluded that their formation is a common down-
stream event in pathogenesis of both sporadic and at least
certain familial forms of ALS. Further, we suggest that c-
synuclein-positive profiles could be formed at early stages
or in particular types of upper motor neuron atrophy due
to their presence not only in cases with profound loss of
upper motor neurons and severe damage to descending
motor fibers, but also in cases with mild changes to these
neurons and their axons.
The ability of wild type c-synuclein to form aggregates
and fibrils in vivo has been previously demonstrated in
mouse models.18,28 The presence of detergent-insoluble c-
synuclein species in the extracts from the profile-positive
dorsolateral column but not from the profile-negative
areas suggests the profiles observed in the spinal cord of
ALS patients are also composed of aggregated c-synuclein.
Normally c-synuclein is abundant in axons of upper
and lower motor neurons18–21 and therefore it is feasible
to link the formation of the profiles with aggregation of
c-synuclein in axons due to or followed by their struc-
tural damage. A rod-like appearance of these structures
on longitudinal sections is consistent with this suggestion.
However, absence of neurofilament proteins within pro-
files argues against a simple explanation that they are
remnants of damaged axons. In the previous studies we
have demonstrated the loss of neurofilament staining in
axons of cultured neurons upon overexpression of c-syn-
uclein20 and decreased abundance of neurofilament pro-
teins in the sciatic nerve of transgenic mice
overexpressing this protein.18,25 Although a molecular
mechanism linking abnormal levels of c-synuclein with
disturbances of neurofilament metabolism or integrity of
the neurofilament network is not clear, it is tempting to
suggest that similar processes may contribute to the
development of axonal pathology in ALS. It is feasible
that at some stage of the pathology progression the local
concentration of c-synuclein in axons of upper motor
neurons might increase, which in turn might trigger the
loss of neurofilaments and aggregation of accumulating c-
synuclein with both processes contributing to further axo-
nal damage.
Transmission of aggregated, axon-derived c-synuclein
species to a specific sub-class of astrocytes expressing
Mac-2/galectin-3, a protein also linked to ALS,29 has been
recently demonstrated in the optic nerve of a mouse
model of glaucoma,28 which may explain previously
observed accumulation of c-synuclein in the optic nerve
astrocytes of human glaucoma patients.24 Detection of
some of the corticospinal tract c-synuclein-positive pro-
files within Mac-2/galactin-3-positive cells allowed us to
hypothesize that a similar process involving phagocytic
cells occurs in the spinal cord of some ALS patients.
The presence of c-synuclein-positive inclusions in the
cell bodies of motor neurons, although rare, demonstrates
that aggregation of this protein in neurons of ALS
patients is not restricted to the axonal compartment. Both
axonal pathology and cytoplasmic inclusions were also
observed in transgenic mice overexpressing c-synuc-
lein.18,25 Further studies should reveal relationships
between the two types of pathological structures described
here and their contribution to the pathogenesis of ALS.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. Western blot analysis of c-synuclein in pro-
tein fractions obtained by sequential extraction of the
dorsolateral column area samples of sALS patients
with (+ve) or without (ve) c-synuclein profiles and
one of healthy controls as well as the motor cortex
samples of a FTLD-MND and control patients. Frac-
tion designations as in Figure 2. Note that for these
Western blots PMS and HS samples were diluted 100
times comparing to those used for the blot shown in
Figure 2.
Table S1. Clinical characteristic ALS patients with c-syn-
uclein-positive inclusions detected in the cell bodies of
spinal motor neurons
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